The Pulmonary Embolism drugs in development market research report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pulmonary Embolism. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Pulmonary Embolism by 16 companies/universities/institutes. The top development phase for Pulmonary Embolism is phase i with five drugs in that stage. The Pulmonary Embolism pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pulmonary Embolism pipeline products market are: Kolmar Korea, Bio-Synectics and Bayer.
The key targets in the Pulmonary Embolism pipeline products market include Coagulation Factor X, Alpha 2 Antiplasmin, and Plasminogen.
The key mechanisms of action in the Pulmonary Embolism pipeline product include Coagulation Factor X Inhibitor with three drugs in Phase I. The Pulmonary Embolism pipeline products include four routes of administration with the top ROA being Intravenous and five key molecule types in the Pulmonary Embolism pipeline products market including Monoclonal Antibody, and Small Molecule.
Pulmonary Embolism overview
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat, and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.
For a complete picture of Pulmonary Embolism’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
